FREE TREATMENT REPORT
See ratings and reviews when you sign up for an account.
Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib
This study is currently Recruiting
July 2011 By M.D. Anderson Cancer Center
First Recieved on November 17, 2009
Last Updated on July 20, 2011
The goal of this research study is to learn more about pain and other symptoms that patients
may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or
||Observational Model: Case-Only, Time Perspective: Prospective
Resources/Links provided by NLM:
|Study Start Date:
|Estimated Primary Completion Date:
|Questionnaire + Sensory Tests + Interview:|
3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
|Ages Eligible for Study:||18 Years|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
1. Patients >= 18 years old.
2. Patients must be fluent with the English language.
3. Patients must be on chemotherapy regimes with any of the study drugs: cisplatin,
oxaliplatin, taxanes and/or bortezomib.
1. Significant cognitive impairment as determined by the trained research staff
2. Chronic alcoholism or substance abuse
3. Diagnosis of severe depression
- Investigator: Sonika Agarwal, MD - Study Chair - UT MD Anderson Cancer Center